Abstract 1489P
Background
In light of the expanding utilization of electronic patient-reported outcomes (ePROs) in healthcare settings, their integration into the standard practice of palliative care remains uncertain. This investigation aimed to identify the determinants linked with adherence to ePRO utilization within a Cancer Network in Brazil.
Methods
Eligible patients had metastatic solid cancer with an expected survival of over 3 months. They were enrolled in monthly ePRO assessments using the Integrated Palliative Outcome Scale (IPOS). Patients failing to complete assessments received one reminder. We conducted multivariate regression analyses to examine the factors influencing adherence. Patient characteristics (age, gender, marital status, education level, and cancer type), along with initial responses on the IPOS, were included as predictors. Follow-up time within palliative care was controlled for in the analysis.
Results
A total of 494 patients were included, with a median age of 67 years (range: 22-94). Most were female (56.1%), married (58.9%), and had at least high school education (77.7%). Most were diagnosed with gastrointestinal (33.2%), breast (20.2%), and genitourinary (14.8%) cancers. Patients had a median follow-up time within palliative care of 10.5 months (range: 3-63 months). Notably, younger age (β=-0.3, SE=0.01, p=0.004), female gender (β=-0.7, SE=0.36, p=0.03) and higher education (β =0.1, SE = 0.06, p = 0.009) were associated with higher ePRO adherence. Interestingly, lower initial assessment score was linked with increased ePRO adherence (p=0.002). Patients experiencing loss of appetite (β=0.4, SE=0.18, p=0.01), having an anxious family member (β=0.3, SE=0.16, p=0.03), and expressing a desire for more information (β=0.2, SE=0.11, p=0.04) also demonstrated higher ePRO adherence.
Conclusions
Our findings underscore the need for tailored approaches to promote patient engagement and improve adherence to ePRO assessments in palliative care settings. Further research exploring interventions targeted at addressing these factors could enhance the integration of ePRO into routine clinical practice, ultimately leading to better patient outcomes and quality of care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10